The five-year award went to UM's Center for Translational Medicine and its partners. The contract is titled "Development of UM-1098: A Novel Synthetic Th17 Inducing Adjuvant and Delivery System."
Drs. Evans and Walid Abdelwahab are the co-principal investigators on the contract, along with their colleagues Drs. David Burkhart, Asia Riel and Blair DeBuysscher with Center for Translational Medicine. The project also includes researchers from the University of Chicago , the Texas Biomedical Research Institute and Missoula-based Inimmune Corp., a corporate development partner .
Related Stories"This funding represents tremendous support for our continuous research efforts in advancing safe and efficient adjuvants and formulation strategies for further development of vaccine candidates against TB," Abdelwahab said. "This contract is a strong endorsement of our exceptional vaccine research team at UM."
"There is extraordinary research ongoing at UM that could positively impact the lives of countless people," Evans said. "Our Vaccine Research Team is dedicated to nurturing and cultivating an interactive research community at UM, specifically geared toward advancing these technologies to help individuals and communities in Montana and across the globe."
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BelfastLive - 🏆 16. / 77 Read more »
Source: shropshirelive - 🏆 55. / 63 Read more »
Source: bbcemt - 🏆 120. / 51 Read more »